AstraZeneca PLC Company Leadership

AZN Stock  USD 67.75  0.51  0.75%   
AstraZeneca PLC employs about 89.9 K people. The company is managed by 47 executives with a total tenure of roughly 388 years, averaging almost 8.0 years of service per executive, having 1912.77 employees per reported executive. Analysis of AstraZeneca PLC's management performance can provide insight into the firm performance.
Pascal Soriot  CEO
CEO, Executive Director and Member of Disclosure Committee
Leif Johansson  Chairman
Non-Executive Independent Chairman of the Board
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

AstraZeneca PLC's latest congressional trading

Congressional trading in companies like AstraZeneca PLC ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AstraZeneca PLC by those in governmental positions are based on the same information available to the general public.
2023-07-10Representative Daniel GoldmanDisposed $100K to $250KVerify
2021-12-01Representative Alan S. LowenthalDisposed Under $15KVerify
2021-07-21Representative Dean PhillipsAcquired Under $15KVerify
2021-04-09Representative Sara JacobsDisposed $15K to $50KVerify
2020-12-01Representative Greg GianforteAcquired Under $15KVerify
2020-01-15Representative John RutherfordDisposed Under $15KVerify
2019-03-11Senator Shelley Moore CapitoAcquired Under $15KVerify

AstraZeneca PLC Management Team Effectiveness

The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of March 2024, Return On Assets is likely to grow to 0.10, while Return On Capital Employed is likely to drop 0.11. At this time, AstraZeneca PLC's Asset Turnover is very stable compared to the past year.
As of the 29th of March 2024, Net Income Applicable To Common Shares is likely to grow to about 3.2 B, while Common Stock Shares Outstanding is likely to drop about 2.9 B.

AstraZeneca PLC Workforce Comparison

AstraZeneca PLC ADR is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 2.99 Million. AstraZeneca PLC holds roughly 89,900 in number of employees claiming about 3% of equities under Health Care industry.

AstraZeneca PLC Profit Margins

The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.870.8195
Notably Up
Very volatile
Net Profit Margin0.10.13
Significantly Down
Slightly volatile
Operating Profit Margin0.220.1788
Fairly Up
Slightly volatile
Return On Assets0.10.0589
Way Up
Slightly volatile
Return On Equity0.140.1521
Significantly Down
Slightly volatile

AstraZeneca PLC ADR Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. AstraZeneca PLC ADR Price Series Summation is a cross summation of AstraZeneca PLC price series and its benchmark/peer.

AstraZeneca PLC Notable Stakeholders

An AstraZeneca PLC stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AstraZeneca PLC often face trade-offs trying to please all of them. AstraZeneca PLC's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AstraZeneca PLC's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal SoriotCEO, Executive Director and Member of Disclosure CommitteeProfile
Leif JohanssonNon-Executive Independent Chairman of the BoardProfile
Luke MielsExecutive Vice-President GPPSProfile
Sean BohenChief Medical Officer, Executive Vice President - Global Medicines DevelopmentProfile
Paul HudsonExecutive Vice President North AmericaProfile
Jose BaselgaExecutive Vice President - Research & Development OncologyProfile
Katarina AgeborgExecutive Vice President - Sustainability, Chief Compliance OfficerProfile
Mark MallonExecutive Vice President InternationalProfile
Fiona CicconiExecutive Vice President - Human ResourcesProfile
Leon WangExecutive Vice President - International and China PresidentProfile
Pam ChengExecutive Vice-President of Operations and Information TechnologyProfile
Ruud DobberExecutive Vice President, BioPharmaceuticals BusinessProfile
David FredricksonExecutive Vice-President Global Head Oncology Business UnitProfile
Bahija JallalExecutive Vice President MedImmuneProfile
Menelas PangalosExecutive Vice President - Research & Development BioPharmaceuticalsProfile
Iskra ReicExecutive Vice President - Europe and CanadaProfile
David SmithExecutive VP of Operations and Information ServicesProfile
Marc DunoyerChief Financial Officer, Executive DirectorProfile
Sherilyn McCoyNon-Executive Independent DirectorProfile
Genevieve BergerNon-Executive Independent DirectorProfile
Nazneen RahmanNon-Executive Independent DirectorProfile
JeanPhilippe CourtoisNon-Executive Independent DirectorProfile
Tony MokNon-Executive Independent DirectorProfile
Deborah DiSanzoNon-Executive Independent DirectorProfile
Shriti VaderaNon-Executive Independent DirectorProfile
Ann CairnsNon-Executive DirectorProfile
Cornelia BargmannNon-Executive DirectorProfile
Tim JacksonSmithNon-Executive DirectorProfile
Michel DemareNon-Executive Independent DirectorProfile
Graham ChipchaseSenior Non-Executive Independent DirectorProfile
Baroness VaderaNon-Executive Independent DirectorProfile
Philip BroadleyNon-Executive Independent DirectorProfile
Rudolph MarkhamNon-Executive Independent DirectorProfile
Weiying WangNon-Executive DirectorProfile
Bruce BurlingtonNon-Executive Independent DirectorProfile
Marcus WallenbergNon-Executive DirectorProfile
Deborah EldracherNon-Executive Independent DirectorProfile
Thomas LarsenIR Contact OfficerProfile
Chris SheldonHead RelationsProfile
Adrian KempCompany SecretaryProfile
Susan MDExecutive DevelopmentProfile
MBA DVMCEO DirectorProfile
Aradhana MDCFO DirectorProfile
Narayan SeshadriIndependent DirectorProfile
Jeffrey PottGeneral CounselProfile
Gonzalo VinaHead RelationsProfile
Andrew BarnettHead RelationsProfile

About AstraZeneca PLC Management Performance

The success or failure of an entity such as AstraZeneca PLC ADR often depends on how effective the management is. AstraZeneca PLC management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AstraZeneca management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AstraZeneca management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.12  0.11 
Return On Assets 0.06  0.10 
Return On Equity 0.15  0.14 
The data published in AstraZeneca PLC's official financial statements usually reflect AstraZeneca PLC's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AstraZeneca PLC ADR. For example, before you start analyzing numbers published by AstraZeneca accountants, it's critical to develop an understanding of what AstraZeneca PLC's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of AstraZeneca PLC's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AstraZeneca PLC's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AstraZeneca PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AstraZeneca PLC ADR. Please utilize our Beneish M Score to check the likelihood of AstraZeneca PLC's management manipulating its earnings.

AstraZeneca PLC Workforce Analysis

Traditionally, organizations such as AstraZeneca PLC use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AstraZeneca PLC within its industry.

AstraZeneca PLC Manpower Efficiency

Return on AstraZeneca PLC Manpower

Revenue Per Employee509.6K
Revenue Per Executive974.7M
Net Income Per Employee76.7K
Net Income Per Executive146.8M
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for AstraZeneca Stock analysis

When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.059
Dividend Share
2.9
Earnings Share
1.9
Revenue Per Share
2.4547
Quarterly Revenue Growth
0.073
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.